

ÁGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain

Villagrasa P¹, Ciruelos E², Llobart A³, De la Peña L¹, Vazquez J¹, Alonso V¹, Vivancos A⁴

1. SOLTI Breast Cancer Research Group, Barcelona; 2. Hospital Universitario Doce de Octubre, Madrid;
3. Hospital Arnau de Vilanova, Valencia; 4. Hospital Vall d'Hebron, Barcelona.


BACKGROUND

Metastatic breast cancer continues to be a major cause of cancer death among women globally. In recent years, a better understanding of tumor biology, namely, many molecular drivers of the disease, and the availability of high throughput technologies, has enabled the emergence of precision medicine bringing new expectations. Furthermore, the shift from single-biomarker focus to the simultaneous examination of large numbers of alterations in order to optimize drug development has resulted in the rise of molecular screening programs worldwide. In Spain, however, only a few institutions have implemented such initiatives. With this in mind, SOLTI, as collaborative network, aims to expand the access to enabling technologies and expertise to perform molecular screening of patients and facilitate their access to clinical trials with novel targeted agents


OBJECTIVES

During this pilot stage, our primary objective is to determine the success rate in including patients in trials based on their molecular profile. Additional aims are to identify technical and logistical barriers to the implementation of a nationwide program, to describe the genomic profiles of the tumors, and to assess patient outcomes.

STUDY DESIGN




SAMPLE ANALYSIS



ABL1	FGFR1	KIT	PIK3R1
AKT1	FGFR2	KRAS	PIK3R5
AKT2	FGFR3	MAG	PTEN
AKT3	FGFR4	MAP2K1	RB1
APC	FLT3	MET	RET
BRAF	GATA1	MLH1	RUNX1
CDH1	GNA11	MPL	SMAD4
CDKN2A	GNAQ	MSH6	SMARCB1
CSF1R	GNAS	MYC	SRC
CTNNB1	GSK3B	NF2	STK11
EGFR	HRAS	NOTCH1	TP53
ERBB2	IDH1	NOTCH4	VHL
ERBB3	IDH2	NRAS	
ESR1	JAK1	PDGFRA	
FBXW7	JAK3	PIK3CA	

PARTICIPATING SITES AND LOGISTICS



STATUS AND FUTURE PERSPECTIVES

AGATA is the first multi-institutional molecular screening program ever implemented in Spain. Patient recruitment started in October 2014 and is expected to conclude in 30 months. Upon completion of the pilot stage, additional patients will be included in an expanded network of hospitals and laboratories.

ACKNOWLEDGEMENTS

Funding provided by Novartis and Fundación Mutua Madrileña.